A c t i o n | 29 Jun 2025 20:44:48 ET │ 13 pages Innovent (1801.HK) R&D Day Takeaways: Leading the Development of Next-Generation IO + ADC CITI'S TAKE During the R&D day, KoLs highlighted promising data of IBI363 in NSCLC, mucosal/acral melanoma and MSS CRC, and its potential to become a cornerstone product for next-generation IO treatment. Innovent is leading the development of next generation of IO+ADC combinations, which could bring broader-spectrum, highly-potent, less-toxic, innovative cancer treatment ...